{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-268185","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.745125+00:00","generated_at":"2026-06-09T02:38:28.340099+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Atara Biotherapeutics establishes $100M ATM equity facility with TD Cowen","bullets":["Entered into an at-the-market (ATM) sales agreement with TD Cowen for up to $100M in common stock.","Commission of up to 3.0% on gross proceeds; company controls timing and size of sales.","Replaces existing 2021 ATM facility once new shelf registration statement becomes effective.","No sales permitted until the registration statement is declared effective by the SEC."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-268185","json":"https://secwatch.observer/filing/0001193125-23-268185.json","markdown":"https://secwatch.observer/filing/0001193125-23-268185.md","text":"https://secwatch.observer/filing/0001193125-23-268185.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000119312523268185/0001193125-23-268185-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000119312523268185/d527002d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T02:38:28.340099+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}